Kirjallisuutta pneumokokkirokotuksista

Tälle sivulle on koottu pneumokokkirokotteita koskevat lähdeviitteet.

Konjugaattirokotteiden teho lapsilla ja pikkulasten ohjelman epäsuora vaikuttavuus

  1. Black S, Shinefield H, Fireman B, et al, and the Northern California Kaiser Permanente Vaccine Study Center Group. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J 2000; 19: 187–95.
  2. Whitney CG, Farley MM, Hadler J, et al, and the Active Bacterial Core Surveillance of the Emerging Infections Program Network. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003; 348: 1737–46.
  3. Pilishvili T, Lexau C, Farley MM, et al, and the Active Bacterial Core Surveillance/Emerging Infections Program Network. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010; 201: 32–41.
  4. Miller E, Andrews NJ, Waight P, Slack M, George R. Herd immunity and serotype replacement four years after pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect Dis 2011; 11: 760–68.
  5. Waight PA, Andrews NJ, Ladhani SN, et al. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: An observational cohort study. Lancet Infect Dis. 2015;15(5):535-543. doi: 10.1016/S1473-3099(15)70044–7 
  6. Steens A, Bergsaker MA, Aaberge IS, et al. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway. Vaccine. 2013;31(52):6232-6238. doi: 10.1016/j.vaccine.2013.10.032
  7. Harboe ZB, Dalby T, Weinberger DM,et al. Impact of 13-Valent Pneumococcal Conjugate Vaccination in Invasive Pneumococcal Disease Incidence and Mortality. Clinical Infectious Diseases 2014;59(8):1066–73
  8. van der Linden M, Falkenhorst G, Perniciaro S, et al. Effects of Infant Pneumococcal Conjugate Vaccination on Serotype
    Distribution in Invasive Pneumococcal Disease among Children and Adults in Germany. PLoS ONE 2015. 10(7): e0131494. doi:10.1371/journal.pone.0131494
  9. Knol MJ, Wagenvoort GH, Sanders EA, et al. Invasive pneumococcal disease 3 years after introduction of 10-valent pneumococcal conjugate vaccine, the Netherlands. 
    Emerg Infect Dis. 2015;21(11):2040-2044. doi: 10.3201/eid2111.140780

  10. De Wals P, Lefebvred B, Markowskie F, et al. Impact of 2 + 1 pneumococcal conjugate vaccine program in the province of Quebec, Canada. Vaccine 2014. 32:1501–1506.

PCV10-rokotteen teho ja vaikuttavuus Suomessa 

  1. Palmu AA, Jokinen J, Borys D, et al. Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial. Lancet 2013;381:214–222.
  2. Palmu AA, Jokinen J, Nieminen H, et al. Vaccine effectiveness of the pneumococcal Haemophilus influenzae protein D conjugate vaccine against clinically suspected non-laboratory-confirmed invasive pneumococcal disease in a cluster-randomized trial. Lancet Resp Med Early Online Publication, 8 August 2014, doi:10.1016/S2213-2600(14)70139-0.
  3. Palmu AA, Jokinen J, Nieminen H, et al. Effect of pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) on outpatient antimicrobial purchases: a double-blind, cluster randomised phase 3-4 trial. Lancet Infect Dis 2014;14:205–212.
  4. Palmu AA, Jokinen J, Nieminen H,  et al. Effectiveness of the Ten-valent Pneumococcal Conjugate Vaccine Against Tympanostomy Tube Placements in a Cluster-randomized Trial. The Pediatric Infectious Disease Journal 2015. 34(11):1230–1235.
  5. Jokinen J, Rinta-Kokko H, Siira L et al. Impact of Ten-Valent Pneumococcal Conjugate Vaccination on Invasive Pneumococcal Disease in Finnish Children – A Population-Based Study. PLoS ONE 2015. 10(3):e0120290. doi:10.1371/journal.pone.0120290
  6. Palmu AA, Kilpi TM, Rinta-Kokko H, et al.Pneumococcal Conjugate Vaccine and Clinically Suspected Invasive Disease. Pediatrics 2015. 136(1) DOI: 10.1542/peds.2015–0458
  7. Palmu AA, Rinta-Kokko H, Nohynek H, et al. Impact of ten-valent pneumococcal conjugate vaccine on pneumonia in Finnish children in a nation-wide population-based study. PLoS ONE 2017. 12(3):e0172690. doi:10.1371/journal.pone.0172690
  8. Palmu AA, Rinta-Kokko H, Nohynek H, et al. Impact of national ten-valent pneumococcal conjugate vaccine program on reducing antimicrobial use and
    tympanostomy tube placements in Finland. Pediatr Infect Dis J 2018;37:97–102. doi: 10.1097/INF.0000000000001810
  9. Rinta-Kokko H, Palmu AA, Auranen K, et al. Long-term impact of 10-valent pneumococcal conjugate vaccination on invasive pneumococcal disease among children in Finland. Vaccine 2018, published online doi: 10.1016/j.vaccine.2018.03.001

Konjugaattirokotteiden teho ikääntyneillä

  1. Bonten M, Bolkenbaas M, Huijts S, et al. Community acquired pneumonia immunisation trial in adults (CAPITA). Pneumonia 2014, Vol 3 
  2. Bonten MJM et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. NEJM 2015;372:1114–1125.
  3. van Werkhoven et al. The Impact of Age on the Efficacy of 13-valent Pneumococcal Conjugate Vaccine in Elderly. CID 2015;61(12):1835–8.
  4. Suaya JA et al. Post hoc analysis of the efficacy of the 13-valent pneumococcal conjugate vaccine against vaccine-type community-acquired pneumonia in at-risk older adults. Vaccine. 2018 Mar 7;36(11):1477–1483.
  5. Gessner BD et al. A public health evaluation of 13-valent pneumococcal conjugate vaccine impact on adult disease outcomes from a randomized clinical trial in the Netherlands. Vaccine. 2018 May

Polysakkaridirokotteen teho ikääntyneillä

  1. Andrews NJ, Waight PA, George RC, Slack MP, Miller E. Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales. Vaccine. 2012 Nov 6;30(48):6802-8. doi: 10.1016/j.vaccine.2012.09.019. Epub 2012 Sep 18.
  2. Moberley S, Holden J, Tatham DP, Andrews RM: Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 1, 2013
  3. Koivula I, Stén M, Leinonen M, Mäkelä PH. Clinical efficacy of pneumococcal vaccine in the elderly: a randomized, single-blind population-based trial. Am J Med. 1997 Oct;103(4):281–90.
  4. Honkanen PO, Keistinen T, Miettinen L, Herva E, Sankilampi U, Läärä E, Leinonen M, Kivelä SL, Mäkelä PH. Incremental effectiveness of pneumococcal vaccine on simultaneously administered influenza vaccine in preventing pneumonia and pneumococcal pneumonia among persons aged 65 years or older. Vaccine. 1999 Jun 4;17(20-21):2493–500.
  5. Ortqvist A, Hedlund J, Burman LA, Elbel E, Höfer M, Leinonen M, Lindblad I, Sundelöf B, Kalin M. Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Swedish Pneumococcal Vaccination Study Group. Lancet. 1998 Feb 7;351(9100):399–403.
  6. Jackson LA, Neuzil KM, Yu O, et al. Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Engl J Med 2003; 348: 1747–55.
  7. Cornu C, Yzebe D, Leophonte P, Gaillat J, Boissel JP, Cucherat M. Efficacy of pneumococcal polysaccharide vaccine in immunocompetent adults: a meta-analysis of randomized trials. Vaccine. 2001 Sep 14;19(32):4780–90.
  8. Fine MJ, Smith MA, Carson CA, et al. Efficacy of pneumococcal vaccination in adults: a metaanalysis of randomized controlled trials. Arch Intern Med 1994;154:2666–77.

Päivitetty: